Belarus has moved responsibility for registering maximum manufacturer selling prices for medicines to its pharmaceutical supervisory body, changing the company-facing administration of the national price-registration system.
Council of Ministers Resolution No. 378 (Постановление Совета Министров Республики Беларусь № 378) was adopted on 27 July, published on 29 July and took effect on 30 July. It amends the 2018 framework governing registration of maximum manufacturer prices.
Under the revised rules, the State Pharmaceutical Supervision in the Sphere of Circulation of Medicines (Государственный фармацевтический надзор в сфере обращения лекарственных средств «Госфармнадзор», Gosfarmnadzor) replaces the Centre for Examinations and Tests in Health Care (Центр экспертиз и испытаний вздравоохранении) throughout the price-registration procedure.
Gosfarmnadzor is also designated as the authorised body for the relevant administrative procedure. The resolution updates the legal wording governing the state register of maximum manufacturer selling prices accordingly.
The change forms part of a wider transfer of pharmaceutical and medical-device regulatory responsibilities to Gosfarmnadzor. The existing price-calculation methodology and substantive criteria remain in place, so the immediate effect for applicants is a change in the authority responsible for price-registration administration rather than in how maximum prices are determined.
Source: Council of Ministers of the Republic of Belarus
Link: Постановление Совета Министров Республики Беларусь от 27 июля 2026 года №378 «Об изменениипостановлений Совета Министров Республики Беларусь» (Council of Ministers Resolution No. 378 of 27 July 2026 on amendments to Council of Ministers resolutios)
Date: 29 July 2026
